论文部分内容阅读
目的探讨恶性血液病患者血清Tpo水平与血小板数量的关系及其临床意义。方法夹心酶联免疫法测定 4 0例恶性血液病人血清Tpo水平 ,同时用自动血细胞分析仪测定其血小板数。结果急慢性白血病病人血清Tpo水平均显著高于正常 (P <0 0 1) ,其它恶性血液病的水平低于正常(P <0 0 0 1) ;急性白血病及其它恶性血液病的PLT低于正常 (P <0 0 0 1) ,其Tpo水平与PLT数呈负相关 (r=- 0 .78,r =- 0 .6 2 ,P均 <0 0 0 5 ) ,慢性白血病组Tpo与血小板数不相关 (r=- 0 .2 3,P >0 0 5 )。结论恶性血液病人Tpo与PLT的关系呈异质性。除白血病外 ,其它恶性血液病人当血小板减少时 ,应用重组人Tpo治疗可能是有益的
Objective To investigate the relationship between serum Tpo and platelet count in patients with hematologic malignancies and its clinical significance. Methods Serum Tpo levels were measured in 40 patients with malignant blood by sandwich enzyme-linked immunosorbent assay, and the platelet count was measured by automatic hematology analyzer. Results The serum levels of Tpo in patients with acute and chronic leukemia were significantly higher than those in normal (P <0.01) and those in other malignant hematological diseases were lower than normal (P <0.01). PLT in acute leukemia and other hematologic malignancies was lower than (P <0.01), the level of Tpo was negatively correlated with the number of PLT (r = - 0.78, r = - 0.62, P <0.05) The number is irrelevant (r = - 0 .2 3, P> 0 0 5). Conclusion The relationship between Tpo and PLT in patients with hematologic malignancy is heterogeneous. In addition to leukemia, it may be beneficial to use recombinant human Tpo therapy when thrombocytopenia is present in other hematologic malignancies